CY1115908T1 - Υγρη συνταγοποιηση προϊοντος συζευξης g-csf - Google Patents

Υγρη συνταγοποιηση προϊοντος συζευξης g-csf

Info

Publication number
CY1115908T1
CY1115908T1 CY20141100501T CY141100501T CY1115908T1 CY 1115908 T1 CY1115908 T1 CY 1115908T1 CY 20141100501 T CY20141100501 T CY 20141100501T CY 141100501 T CY141100501 T CY 141100501T CY 1115908 T1 CY1115908 T1 CY 1115908T1
Authority
CY
Cyprus
Prior art keywords
composition
salts
product
colony stimulating
granulocyte colony
Prior art date
Application number
CY20141100501T
Other languages
English (en)
Inventor
Walter Hinderer
Christian Scheckermann
Original Assignee
Ratiopharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ratiopharm Gmbh filed Critical Ratiopharm Gmbh
Publication of CY1115908T1 publication Critical patent/CY1115908T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer

Abstract

Η παρούσα εφεύρεση αφορά σε μία υγρή φαρμακευτική σύνθεση περιλαμβάνουσα πολυπεπτίδιο παράγοντα διέγερσης αποικίας κοκκιοκυττάρου συζευγμένο με ένα πολυμερές, η δε σύνθεση έχει τιμή pΗ στην περιοχή 4,5 έως 5,5. Η σύνθεση περαιτέρω περιλαμβάνει επιφανειοδραστικό και προαιρετικώς ένα ή περισσότερα άλλα φαρμακευτικώς αποδεκτά έκδοχα. Περαιτέρω, η σύνθεση της εφεύρεσης είναι ελεύθερη τρυγικού οξέος ή αλάτων αυτού και ελεύθερη ηλεκτρικού οξέος και αλάτων αυτού, ως ρυθμιστικοί παράγοντες και δεν περιέχει αμινοξέα ως σταθεροποιητή. Η σύνθεση έχει καλή σταθερότητα αποθήκευσης και ειδικώς είναι χρήσιμη για την προφύλαξη και τη θεραπεία διαταραχών και ιατρικών ενδείξεων όπου παρασκευάσματα παράγοντα διέγερσης αποικίας κοκκιοκυττάρου θεωρούνται ως χρήσιμες θεραπείες.
CY20141100501T 2007-08-27 2014-07-03 Υγρη συνταγοποιηση προϊοντος συζευξης g-csf CY1115908T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07115047 2007-08-27
EP08787525.8A EP2197919B1 (en) 2007-08-27 2008-08-27 Liquid formulation of g-csf conjugate

Publications (1)

Publication Number Publication Date
CY1115908T1 true CY1115908T1 (el) 2017-01-25

Family

ID=39862881

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100501T CY1115908T1 (el) 2007-08-27 2014-07-03 Υγρη συνταγοποιηση προϊοντος συζευξης g-csf

Country Status (24)

Country Link
US (1) US8546328B2 (el)
EP (2) EP2578235A3 (el)
JP (2) JP5570988B2 (el)
KR (1) KR20100052501A (el)
CN (2) CN101827864A (el)
AU (1) AU2008292186B9 (el)
BR (1) BRPI0815975B8 (el)
CA (1) CA2696594C (el)
CY (1) CY1115908T1 (el)
DE (1) DE202008017456U1 (el)
DK (1) DK2197919T3 (el)
EA (1) EA020069B1 (el)
ES (1) ES2476915T3 (el)
HR (1) HRP20140590T1 (el)
IL (1) IL204190A (el)
MX (1) MX2010002448A (el)
NZ (1) NZ583276A (el)
PL (1) PL2197919T3 (el)
PT (1) PT2197919E (el)
RS (1) RS53404B (el)
SI (1) SI2197919T1 (el)
UA (1) UA98001C2 (el)
WO (1) WO2009027437A1 (el)
ZA (1) ZA201000798B (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE034398T2 (en) * 2010-01-19 2018-02-28 Hanmi Science Co Ltd Liquid preparations for sustained G-CSF conjugate
EA022821B1 (ru) 2010-03-17 2016-03-31 Ратиофарм Гмбх Способ получения биологически активного рекомбинантного г-ксф человека
EP2384759A1 (en) 2010-05-06 2011-11-09 Suomen Punainen Risti Veripalvelu Sulphated hyaluronic acid in combination with G-CSF for use in mobilising blood stem cells
WO2017181920A1 (zh) * 2016-04-18 2017-10-26 江苏恒瑞医药股份有限公司 一种重组人粒细胞集落刺激因子的制备方法
IT201700108526A1 (it) * 2017-09-28 2019-03-28 Alfasigma Spa Composizioni orali per il trattamento del refluso gastroesofageo.
EP3773468A2 (en) * 2018-05-04 2021-02-17 Ilkogen Ilaç Sanayi ve Ticaret A.S. Stable hybrid fc fusion g-csf formulation
CN114224853B (zh) * 2022-01-04 2022-09-23 山东新时代药业有限公司 聚乙二醇化重组人粒细胞刺激因子注射用冻干制剂
WO2024037633A2 (en) * 2022-08-19 2024-02-22 Evive Biotechnology (Shanghai) Ltd Formulations comprising g-csf and uses thereof

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479268A (en) 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
CH596313A5 (el) 1975-05-30 1978-03-15 Battelle Memorial Institute
US4414147A (en) 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
US5675941A (en) 1983-12-09 1997-10-14 Dykmans; Maximiliaan J. Method and apparatus for constructing prestressed structures utilizing a membrane and floating dome assembly
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
JP2524586B2 (ja) 1985-06-26 1996-08-14 シタス コーポレイション ポリマ−接合を利用する医薬組成物用蛋白質の可溶化
US6004548A (en) 1985-08-23 1999-12-21 Amgen, Inc. Analogs of pluripotent granulocyte colony-stimulating factor
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
KR0133561B1 (ko) 1988-05-13 1998-04-21 스티븐 엠. 오드레 과립구 군체 자극인자의 정제방법
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US6166183A (en) 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
DE4014750A1 (de) 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
US5399345A (en) 1990-05-08 1995-03-21 Boehringer Mannheim, Gmbh Muteins of the granulocyte colony stimulating factor
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
AU677789B2 (en) 1992-07-02 1997-05-08 Collagen Corporation Biocompatible polymer conjugates
AU5098193A (en) 1992-09-01 1994-03-29 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
AU7097094A (en) 1993-06-01 1994-12-20 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
US5874075A (en) 1993-10-06 1999-02-23 Amgen Inc. Stable protein: phospholipid compositions and methods
EP1090645B1 (en) 1994-02-08 2005-12-07 Amgen Inc., Oral delivery of chemically modified proteins
CA2183871C (en) 1994-02-23 2008-11-04 Motoo Yamasaki Platelet growth accelerator
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
AU725287B2 (en) 1996-02-15 2000-10-12 Novozymes A/S Conjugation of polypeptides
JP2001507215A (ja) 1997-01-16 2001-06-05 サイテル コーポレイション 組換え糖タンパク質のインビトロでの実用的なシアリル化
RO121474B1 (ro) 1997-06-06 2007-06-29 Kyowa Hakko Kogyo Co., Ltd. Polipeptide modificate chimic
US6540672B1 (en) * 1998-12-09 2003-04-01 Novo Nordisk A/S Medical system and a method of controlling the system for use by a patient for medical self treatment
FR2796071B1 (fr) 1999-07-08 2001-09-07 Hoechst Marion Roussel Inc Procede de purification de facteur de stimulation de colonies de granulocytes
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
ES2327606T3 (es) 2000-01-10 2009-11-02 Maxygen Holdings Ltd Conjugados de g-csf.
WO2001064241A1 (fr) 2000-02-29 2001-09-07 Chugai Seiyaku Kabushiki Kaisha Preparations stabilisees a long terme
JP2004528001A (ja) 2000-05-12 2004-09-16 ネオーズ テクノロジーズ， インコーポレイテッド インビトロにおけるフコシル化組換えグリコペプチド
NZ522030A (en) 2000-05-15 2004-11-26 F Erythropoietin composition with a multiple charged inorganic anion i.e. a sulfate a citrate or a phosphate to stabilize the composition
EP1284987B1 (en) 2000-05-16 2007-07-18 Bolder Biotechnology, Inc. Methods for refolding proteins containing free cysteine residues
KR100396983B1 (ko) 2000-07-29 2003-09-02 이강춘 고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체
US20040038878A1 (en) 2000-08-04 2004-02-26 Masahiko Tanikawa Injectable protein formulations
EP1329224A4 (en) 2000-09-01 2004-04-14 Chugai Pharmaceutical Co Ltd PREPARATIONS OF STABILIZED SOLUTIONS OVER A LONG PERIOD OF TIME
ES2606840T3 (es) 2001-10-10 2017-03-28 Ratiopharm Gmbh Remodelación y glicoconjugación de factor estimulante de colonias de granulocitos (G-CSF)
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
SI21102A (sl) 2001-12-19 2003-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
SI21273A (sl) 2002-07-31 2004-02-29 LEK farmacevtska dru�ba d.d. Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina
MXPA06001358A (es) 2003-08-08 2006-05-15 Fresenius Kabi Gmbh Conjugados de hidroxialquil almidon y g-csf.
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
DE10348550A1 (de) * 2003-10-20 2005-06-16 Hexal Biotech Forschungsgmbh Stabile wässrige G-CSF-haltige Zusammensetzungen
EP1682184B1 (en) 2003-11-04 2013-10-16 LEK Pharmaceuticals d.d. Stable pharmaceutical composition comprising granulocyte-colony stimulating factor
CA2549409C (en) 2003-12-03 2013-10-29 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
KR101439880B1 (ko) * 2004-01-08 2014-09-12 라티오팜 게엠베하 펩티드의 오-결합형 글리코실화
EA010501B1 (ru) 2004-03-11 2008-10-30 Фрезениус Каби Дойчланд Гмбх Конъюгаты гидроксиалкилкрахмала и белка, полученные восстановительным аминированием
ES2390885T3 (es) 2004-03-11 2012-11-19 Fresenius Kabi Deutschland Gmbh Conjugados de hidroxialquilalmidón y una proteína
DE102004036909B4 (de) 2004-07-29 2007-04-05 Infineon Technologies Ag Halbleiterbasisbauteil mit Verdrahtungssubstrat und Zwischenverdrahtungsplatte für einen Halbleiterbauteilstapel sowie Verfahren zu deren Herstellung
EP1858543B1 (en) 2005-01-10 2013-11-27 BioGeneriX AG Glycopegylated granulocyte colony stimulating factor
EP1869078A2 (en) 2005-03-17 2007-12-26 Zenotech Laboratories Limited Process for the purification of recombinant granulocyte-colony stimulating factor
CN101193658B (zh) * 2005-06-01 2011-08-31 马克西根控股公司 聚乙二醇化g-csf多肽及其产生方法
EP1762250A1 (en) 2005-09-12 2007-03-14 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine
DE102006009437A1 (de) * 2006-03-01 2007-09-13 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
ITMI20061624A1 (it) 2006-08-11 2008-02-12 Bioker Srl Mono-coniugati sito-specifici di g-csf
PL2144923T3 (pl) 2007-04-03 2013-12-31 Biogenerix Ag Sposoby leczenia z użyciem glikopegilowanego G-CSF
US8207112B2 (en) * 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate

Also Published As

Publication number Publication date
CA2696594C (en) 2019-03-19
NZ583276A (en) 2012-06-29
CN104689333B (zh) 2018-05-29
EP2578235A3 (en) 2013-08-28
KR20100052501A (ko) 2010-05-19
EP2197919A1 (en) 2010-06-23
PL2197919T3 (pl) 2014-09-30
BRPI0815975B8 (pt) 2021-05-25
US8546328B2 (en) 2013-10-01
CA2696594A1 (en) 2009-03-05
BRPI0815975B1 (pt) 2019-04-02
WO2009027437A1 (en) 2009-03-05
EA201070315A1 (ru) 2010-08-30
ES2476915T3 (es) 2014-07-15
IL204190A (en) 2015-01-29
EP2578235A2 (en) 2013-04-10
AU2008292186A1 (en) 2009-03-05
MX2010002448A (es) 2010-10-04
RS53404B (en) 2014-10-31
JP2010536929A (ja) 2010-12-02
JP5836351B2 (ja) 2015-12-24
UA98001C2 (uk) 2012-04-10
CN104689333A (zh) 2015-06-10
JP2014101362A (ja) 2014-06-05
AU2008292186B2 (en) 2014-02-27
BRPI0815975A2 (pt) 2015-02-18
ZA201000798B (en) 2010-10-27
US20110053844A1 (en) 2011-03-03
DE202008017456U1 (de) 2009-08-27
SI2197919T1 (sl) 2014-09-30
JP5570988B2 (ja) 2014-08-13
AU2008292186B9 (en) 2014-07-03
DK2197919T3 (da) 2014-07-07
EA020069B1 (ru) 2014-08-29
HRP20140590T1 (hr) 2014-08-15
PT2197919E (pt) 2014-07-17
EP2197919B1 (en) 2014-04-09
CN101827864A (zh) 2010-09-08

Similar Documents

Publication Publication Date Title
CY1115908T1 (el) Υγρη συνταγοποιηση προϊοντος συζευξης g-csf
CY1118821T1 (el) Γελες με βαση υαλουρονικο οξυ οι οποιες περιλαμβανουν αναισθητικους παραγοντες
CY1124432T1 (el) Φαρμακευτικες συνθεσεις που αποτελουν ν-(3,5-διμεθοδυφαινυλ)-ν'-(1-μεθυλαιθυλ)-ν-[3-(1--μεθυλ-1η-πυραζολ-4-υλ)κινοοξαλιν-6-υλ]αιθανο-1,2-διαμινη
EA200800050A1 (ru) Самобуферирующиеся композиции белков
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
CY1117326T1 (el) Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson
EA201691151A1 (ru) Соединения для лечения пациентов с ros1-мутантными раковыми клетками
BR112015025804A2 (pt) derivados de glutarimida, uso dos mesmos, composição farmacêutica com base neles e métodos para a produção de derivados de glutarimida
AR074471A1 (es) Compuesto 5(5-(2-(3-aminopropoxi) - 6 - metoxifenil) -1h- pirazol-3- ilamino ) pirazin -2-carbonitrilo , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para inhibir chk1 y para tratar cancer
EA200601776A1 (ru) Метадоновые композиции местного действия и способы их применения
MX2010002392A (es) Composiciones de brimonidina mejoradas para tratar eritema.
UA108222C2 (xx) СПОЛУКИ ЗАМІЩЕНОГО N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗОЛ$1,2-а]ПІРИДИН-3-КАРБОКСАМІДУ ЯК ІНГІБІТОРИ cFMS
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
ATE523209T1 (de) Flüssige formulierung von fsh
DE602007010781D1 (de) N- (phenylmethyl) -2- (1h-pyrazol-4-yl) acetamid-derivate als p2x7-antagonisten zur behandlung von schmerzen, entzündungen und neurodegeneration
EA200970981A1 (ru) Пептидная смесь в качестве стабилизатора вина
BR112013004436A2 (pt) composições e usos de materiais com atividade microbicida alta e toxicidade baixa
ATE485037T1 (de) Krebsbehandlung mittels fts und 2-deoxyglucose
MX2011012143A (es) Composiciones adecuadas para el tratamiento topico o infecciones fungicas de la piel y uñas.
CY1111460T1 (el) Μεθανοσουλφονικη 4-[(3-φθοροφαινοξυ) φαινυλο-μεθυλο] πιπεριδινη: χρησεις, διεργασια συνθεσης και φαρμακευτικες συνθεσεις
BR112015022758A2 (pt) derivados de pirrolidina, composições farmacêuticas contendo os mesmos e seu uso em terapia
ATE364044T1 (de) 5ht2c rezeptor agonisten zur behandlung von diabetes und fettleibigkeit